HIT-MESO

HIT-Meso: Hemi-thoracic Irradiation with Proton Therapy in Malignant Pleural Mesothelioma

Trial Summary:

HIT-MESO is a Phase III randomised-controlled study to assess the impact of proton beam therapy (PBT) on patients with unilateral malignant pleural mesothelioma (MPM). The study aims to evaluate whether PBT improves progression-free survival (PFS) and overall survival (OS), while also examining its effects on quality of life and cost-effectiveness compared to standard care. The trial will recruit 148 patients across 18-20 UK sites, with randomisation into two arms. Control arm, standard active surveillance, intervention arm will receive PBT to the hemi-thorax, delivering 50Gy in 25 fractions, with an integrated boost to 60Gy for visible tumours.

RT QA Summary:

All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.

QA ProcessQA ActivityRequired for TrialAdditional Details
Pre-AccrualFacility Questionnaire
Outlining Benchmark Case1 Case
Planning Benchmark Case1 Case
Dummy Run
During AccrualIndividual Case ReviewProspective: First three cases outlining and planning

Retrospective: Patients 4-10
Data collectionAll patients
Dosimetry Audit
QA Streamlining

RTTQA Contact: enh-tr.hit-mesoqa@nhs.net

Chief Investigator: Dr Crispin Hiley

RT Lead: Dr David Woolf

Sponsor: University College London ctc.hit-meso@ucl.ac.uk

Funder: Asthma + Lung UK and Mesothelioma UK